Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Weak
Growth
Earnings
Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Strong
Telephone
61.3.8379.0100
Address
103-113 Stanley Street West Melbourne, Victoria (VIC) 3003
Description
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm develops and commercializes pharmaceutical products using unique technology to administer drugs through the skin. Its products brands include AXIRON, ELLAVIE & EVAMIST and RECUVYRA. The company was founded by Ross Dobinson and Barrie Charles Finnin in 1998 and is headquartered in West Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.1
Trade Value (12mth)
AU$7,055.00
1 week
-3.23%
1 month
-3.23%
YTD
-9.09%
1 year
-48.28%
All time high
4.52
EPS 3 yr Growth
-65.20%
EBITDA Margin
-158.40%
Operating Cashflow
-$4m
Free Cash Flow Return
-53.60%
ROIC
-72.20%
Interest Coverage
N/A
Quick Ratio
1.60
Shares on Issue (Fully Dilluted)
290m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 February 25 |
Issue of Attaching Options initiated, extended Closing Date
×
Issue of Attaching Options initiated, extended Closing Date |
19 February 25 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
19 February 25 |
Appendix 3Y Brumley
×
Appendix 3Y Brumley |
19 February 25 |
Appendix 3Y Brooke
×
Appendix 3Y Brooke |
19 February 25 |
Appendix 3Y Kotsanis
×
Appendix 3Y Kotsanis |
19 February 25 |
Appendix 3Y Oldham
×
Appendix 3Y Oldham |
19 February 25 |
Top20 quoted option holders and distribution schedule
×
Top20 quoted option holders and distribution schedule |
18 February 25 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
18 February 25 |
Notification regarding unquoted securities - ACR
×
Notification regarding unquoted securities - ACR |
13 February 25 |
Appendix 3Y x 4
×
Appendix 3Y x 4 |
13 February 25 |
Cleansing Notice
×
Cleansing Notice |
13 February 25 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
13 February 25 |
Cleansing Notice - Reissued
×
Cleansing Notice - Reissued |
07 February 25 |
Acrux CEO announces plan to retire
×
Acrux CEO announces plan to retire |
03 February 25 |
Results of EGM
×
Results of EGM |
30 January 25 |
Monthly Activities/Appendix 4C Cash Flow Report
×
Monthly Activities/Appendix 4C Cash Flow Report |
21 January 25 |
Update - Proposed issue of securities - ACR
×
Update - Proposed issue of securities - ACR |
17 January 25 |
Prospectus - Options
×
Prospectus - Options |
17 January 25 |
Target Market Determination - Options
×
Target Market Determination - Options |
16 January 25 |
Launch of 90 gram pack size of Dapsone 5%, Gel in US
×
Launch of 90 gram pack size of Dapsone 5%, Gel in US |
03 January 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
23 December 24 |
Acrux raises $1.34 million from SPP
×
Acrux raises $1.34 million from SPP |
23 December 24 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
23 December 24 |
Cleansing Notice
×
Cleansing Notice |
19 December 24 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.